1. Routine blood pressure management:
2. Upper target mean value (mmHg):
3. Lower target mean value (mmHg):
4. Blood pressure augmentation (mmHg):
	1. Mean arterial pressure (MAP):
	2. Systolic blood pressure (SBP):
5. Hemodynamic therapy:

[ ]  Yes, specify:

[ ]  No

1. Hemodynamic augmentation:

[ ]  Yes, specify:

[ ]  No

1. Hypervolemic therapy/volume augmentation:

[ ]  Yes, specify:

[ ]  No

1. Hypervolemic therapy/volume augmentation – specific value:
2. Target for fever management (⁰C):
3. Glucose control:
	1. Upper limit:
	2. Lower limit:
4. Sodium management
	1. Upper Limit
	2. Lower Limit
5. Mechanical ventilation (invasive or noninvasive):

[ ]  Yes

[ ]  No

1. Invasive mechanical ventilation:

[ ]  Yes

[ ]  No

1. Noninvasive mechanical ventilation only:

[ ]  Yes

[ ]  No

1. Total length of mechanical ventilation (days, both invasive and noninvasive):
2. Total duration of invasive mechanical ventilation (days):
3. Total duration of noninvasive mechanical ventilation (days):
4. Osmotherapy for intracranial hypertension or cerebral edema: [ ]  Yes, specify: [ ]  No

General Instructions

This CRF Module is recommended to collect information on ICU therapies for subarachnoid hemorrhage (SAH) studies.

All elements on this CRF are classified as Supplemental and should only be collected if the research team considers them appropriate for their study.

Specific Instructions

Please see the Data Dictionary for definitions for each of the data elements included in this CRF Module.

* Upper/lower target mean value: routine upper/lower targets for mean arterial pressure
* Blood pressure augmentation goal: Blood pressure augmentation goal (MAP or systole) beyond routine upper limit of blood pressure for prevention or treatment of delayed cerebral ischemia
* Hemodynamic therapy – general: Any goal-directed intervention aimed to influence cardiac output or volume status or blood pressure or any combination
* Hemodynamic augmentation – general: An intervention in systemic circulatory status that is aimed at establishing supraphysiological goals in terms of cardiac output or volume status or blood pressure or any combination
* Hypervolemic therapy/volume augmentation – general: An intervention aimed at establishing supraphysiological goals in terms of volume status indicated by means of fluid balance and/or- intake, or cardiac output or central venous pressure/pulmonary artery occlusion pressure (CVP/PAOP) or any combination, thus excluding euvolemia
* Hypervolemic therapy/volume augmentation – specific value: Upper and lower limit of hypervolemic therapy/volume augmentation goal. Fluid balance and/or- intake , or cardiac output or CVP/PAOP or any combination
* Fever management target: Elevated body temp that prompts therapy in ⁰C
* Glucose control – upper/lower limit: Upper/lower value of blood sugar levels that prompt treatment (Units will depend on country of origin)
* Sodium management - upper/lower limit: Upper/lower value of sodium levels that prompt treatment (Units will depend on country of origin)
* Mechanical ventilation: Invasive or noninvasive ventilation at any time excluding strictly procedural/elective mechanical ventilation
* Invasive mechanical ventilation: Yes if intubation and invasive ventilation at any point (regardless if the patient also received non-invasive ventilation before or after) excluding strictly procedural/elective mechanical ventilation
* Noninvasive mechanical ventilation: Yes if patient only received non-invasive ventilation (never intubated excluding strictly procedural/elective intubation) during the hospitalization. This variable should be defined as positive pressure NIV and NOT include patients who receive constructive positive airway pressure (CPAP) at night for obstructive sleep apnea (OSA).
* Osmotherapy: Any use of osmotherapy (mannitol, hypertonic saline or others) for treatment of intracranial hypertension or brain edema

References

Diringer MN, Bleck TP, Claude Hemphill J 3rd, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES Jr, Citerio G, Gress D, Hänggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zipfel G; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211–240.

Suarez JI, Martin RH. Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design. Neurocrit Care. 2010;13(2):263–277.

Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL, Wong J, Harbaugh R; ALISAH Investigators. The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke. 2012;43(3):683–690.

van der Jagt M. Fluid management of the neurological patient: a concise review. Crit Care. 2016;20(1):126.

van der Jagt M, Haitsma I. An injured brain needs cooling down: no. Intensive Care Med. 2015;41(6):1129–1131.